X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32) 32
oncology (28) 28
female (25) 25
index medicus (25) 25
middle aged (21) 21
aged (20) 20
treatment outcome (18) 18
male (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
adult (14) 14
prognosis (12) 12
breast neoplasms - pathology (10) 10
neoplasm staging (10) 10
breast neoplasms - drug therapy (9) 9
chemotherapy (9) 9
disease-free survival (9) 9
neuroendocrine tumors (9) 9
survival (9) 9
cancer (8) 8
expression (8) 8
fluorouracil - administration & dosage (8) 8
tumors (8) 8
aged, 80 and over (7) 7
care and treatment (7) 7
colorectal cancer (7) 7
medicine & public health (7) 7
breast cancer (6) 6
disease progression (6) 6
everolimus (6) 6
oxaliplatin (6) 6
primary chemotherapy (6) 6
trial (6) 6
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
colorectal neoplasms - drug therapy (5) 5
fluorouracil (5) 5
metastasis (5) 5
neuroendocrine tumors - drug therapy (5) 5
organoplatinum compounds - administration & dosage (5) 5
retrospective studies (5) 5
therapy (5) 5
cancer research (4) 4
clinical trials (4) 4
colorectal neoplasms - pathology (4) 4
combination (4) 4
cyclophosphamide - administration & dosage (4) 4
efficacy (4) 4
endocrinology & metabolism (4) 4
immunohistochemistry (4) 4
neoplasm metastasis (4) 4
pancreas (4) 4
research (4) 4
risk factors (4) 4
tamoxifen (4) 4
5-fluorouracil (3) 3
adenocarcinoma - drug therapy (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast neoplasms - metabolism (3) 3
cancer patients (3) 3
capecitabine (3) 3
carcinoma (3) 3
cisplatin (3) 3
classification (3) 3
development and progression (3) 3
drug therapy (3) 3
endothelial growth-factor (3) 3
follow-up studies (3) 3
history (3) 3
kaplan-meier estimate (3) 3
ki-67 antigen - metabolism (3) 3
leucovorin (3) 3
leucovorin - administration & dosage (3) 3
liver neoplasms - drug therapy (3) 3
liver neoplasms - secondary (3) 3
magnetic resonance imaging (3) 3
management (3) 3
metastatic colorectal cancer (3) 3
morphology (3) 3
neoadjuvant chemotherapy (3) 3
pancreatic endocrine tumors (3) 3
pancreatic neoplasms - drug therapy (3) 3
patient outcomes (3) 3
patients (3) 3
phase-ii (3) 3
phase-iii (3) 3
phase-iii trial (3) 3
preoperative chemotherapy (3) 3
prognostic-factors (3) 3
randomized-trial (3) 3
safety (3) 3
toxicity (3) 3
young adult (3) 3
1st-line therapy (2) 2
activation (2) 2
anastrozole (2) 2
angiogenesis (2) 2
angiogenesis inhibitors (2) 2
angiogenesis inhibitors - administration & dosage (2) 2
antimitotic agents (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Anticancer Research, ISSN 0250-7005, 10/2016, Volume 36, Issue 10, pp. 5163 - 5170
Background: Generic anticancer drugs represent an opportunity in terms of cost savings but there are some concerns about their tolerability. The safety... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 17, pp. 2372 - 2377
Purpose Knowledge of clinical course of pancreatic endocrine carcinomas (PECs) is poor. This study aimed to determine the time to progression of advanced PECs,... 
SURVIVAL | DIAGNOSIS | NEUROENDOCRINE TUMORS | PROGNOSTIC-FACTORS | ONCOLOGY | MIDGUT | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Risk Factors | Male | Disease Progression | Disease-Free Survival | Neoplasm Metastasis | Ki-67 Antigen - analysis | Female | Aged | Pancreatic Neoplasms - mortality | Retrospective Studies | Pancreatic Neoplasms - therapy
Journal Article
Endocrinology, Diabetes and Metabolism Case Reports, ISSN 2052-0573, 2014, Volume 2014, pp. 140047 - 140047
Insulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment of the malignant NE disease of the... 
Unusual Effects of Medical Treatment
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1652 - 1664
Journal Article
Human Pathology, ISSN 0046-8177, 02/2018, Volume 72, pp. 144 - 152
Monoclonal antibodies to somatostatin receptors 2A (SSTR2A, UMB-1) and 5 (SSTR5, UMB-4) were reported to be highly reliable for immunohistochemical detection... 
Immunohistochemistry | Neuroendocrine neoplasm | Somatostatin receptor 5 | Somatostatin receptor 2A | Harmonization | Histopathology | Medical imaging | Cloning | Morphology | Classification | Localization | Patients | Cancer | Tumors
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2014, Volume 14, Issue 1, p. 184
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 12/2017, Volume 21, Issue 12, pp. 3670 - 3678
Patients with ischaemic heart disease or chronic heart failure show altered levels of obestatin, suggesting a role for this peptide in human heart function. We... 
cardioprotection | obestatin | ischaemia/reperfusion | coronary flow | myocardial contractility | post‐conditioning | post-conditioning | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | ISOLATED RAT-HEART | INJURY | DES-ACYL GHRELIN | PEPTIDE | CELL BIOLOGY | ischaemia | HORMONE | PROTEIN-COUPLED RECEPTOR | ENDOTHELIAL-CELLS | reperfusion | Endothelin-1 - antagonists & inhibitors | Myocardial Ischemia - genetics | Myocardial Infarction - genetics | Myocardial Ischemia - metabolism | Peptide Hormones - pharmacology | Rats, Wistar | Soluble Guanylyl Cyclase - metabolism | Cardiotonic Agents - metabolism | Endothelin-1 - pharmacology | Myocardial Contraction - drug effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Peptide Hormones - genetics | Cyclic GMP-Dependent Protein Kinases - metabolism | Cyclic GMP-Dependent Protein Kinases - genetics | Proto-Oncogene Proteins c-akt - genetics | Peptide Hormones - metabolism | Potassium Channels - metabolism | Myocardial Reperfusion Injury - pathology | Soluble Guanylyl Cyclase - genetics | Myocardial Infarction - pathology | Papillary Muscles - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Myocardial Reperfusion Injury - genetics | Heart Ventricles - pathology | Organ Culture Techniques | Signal Transduction | Gene Expression Regulation | Myocardial Ischemia - prevention & control | Rats | Cardiotonic Agents - chemistry | Cardiotonic Agents - pharmacology | Myocardial Infarction - metabolism | Myocardial Ischemia - pathology | Potassium Channels - genetics | Phosphatidylinositol 3-Kinases - genetics | Myocardial Reperfusion Injury - metabolism | Animals | Heart Ventricles - metabolism | Myocardial Infarction - prevention & control | Nitric Oxide - metabolism | Papillary Muscles - drug effects | Papillary Muscles - pathology | Myocardial Reperfusion Injury - prevention & control | Heart Ventricles - drug effects | Endothelin | Heart diseases | Vasodilators | Nitric oxide | Reactive oxygen species | Protein kinase C | Peptides | AKT protein | Activation | Heart function | Guanylate cyclase | Signal transduction | Mitochondria | Reperfusion | Ischemia | Ghrelin | Cyclic GMP | Inotropism | Heart failure | Stresses | Cardiovascular system | Cardiac conditioning | Muscles | Pharmacology | Endothelin 1 | Potassium channels | Muscle contraction | Coronary artery disease | Stress | 1-Phosphatidylinositol 3-kinase | Signaling | Cell death | Myocardium | Growth hormone | ATP | Potassium | Original
Journal Article
Endocrine-Related Cancer, ISSN 1351-0088, 06/2018, Volume 25, Issue 6, pp. 607 - 618
No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study,... 
Validation | Prognosis | Overall survival | Prognostic score | Neuroendocrine tumors | SURVIVAL | prognostic score | EVEROLIMUS | PHASE-3 | prognosis | OCTREOTIDE LAR | EUROPE | TRIAL | RADIANT-2 | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | overall survival | SUNITINIB | NOMOGRAM | neuroendocrine tumors | validation | EPIDEMIOLOGY
Journal Article
Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 02/2018, Volume 122, pp. 21 - 29
The available fluoropyrimidines and oxaliplatin combinations for colorectal cancer patients have different safety profiles. The aim of this systematic review... 
5-fluorouracil | Tolerability | Oxaliplatin | Capecitabine | Colorectal cancer | Safety profile | LEUCOVORIN | PHASE-III | FLUOROURACIL | CAPECITABINE PLUS OXALIPLATIN | ONCOLOGY | 1ST-LINE THERAPY | HEMATOLOGY | MODULATION | Antimitotic agents | Cancer patients | Care and treatment | Safety and security measures | Drug therapy | Antineoplastic agents | Cancer
Journal Article
Gastroenterology, ISSN 0016-5085, 08/2018, Volume 155, Issue 2, pp. 479 - 489.e7
Metformin seems to have anticancer effects. However, it is not clear whether use of glycemia and metformin affect outcomes of patients with advanced pancreatic... 
Drug | Pancreas | Chemoprevention | Insulin Resistance | METAANALYSIS | RISK | CELL-PROLIFERATION | CANCER | INSULIN | PHASE-II TRIAL | IMPACT | METABOLISM | GASTROENTEROLOGY & HEPATOLOGY | LANREOTIDE | Diabetics | Analysis | Patient outcomes | Development and progression | Metformin | Angiogenesis inhibitors | Tumors
Journal Article